Information:
Error:
ID
34524
Description
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE); ODM derived from: https://clinicaltrials.gov/show/NCT01384461
Link
https://clinicaltrials.gov/show/NCT01384461
Keywords
Versions (1)
- 1/18/19 1/18/19 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
January 18, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Rheumatoid Arthritis NCT01384461
Eligibility Rheumatoid Arthritis NCT01384461
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT01384461
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Adult | Age
Item
adult patients, >/= 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Rheumatoid arthritis disease activity, moderate | Rheumatoid Arthritis Severe
Item
moderate to severe rheumatoid arthritis
boolean
C2368567 (UMLS CUI [1])
C0003873 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0003873 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
RoActemra | Actemra
Item
roactemra/actemra treatment initiated by rheumatologist in an arthritis center for (up to 2 months prior to study entry)
boolean
C3272237 (UMLS CUI [1])
C2740854 (UMLS CUI [2])
C2740854 (UMLS CUI [2])
Allergic Reaction Severe Investigational New Drug Component | Anaphylaxis Severe Investigational New Drug Component | Hypersensitivity Investigational New Drug Component
Item
history of severe allergic or anaphylactic reactions or known hypersensitivity to any component of the drug
boolean
C1527304 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C1705248 (UMLS CUI [1,4])
C0002792 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C1705248 (UMLS CUI [2,4])
C0020517 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C1705248 (UMLS CUI [3,3])
C0205082 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C1705248 (UMLS CUI [1,4])
C0002792 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C1705248 (UMLS CUI [2,4])
C0020517 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C1705248 (UMLS CUI [3,3])
Communicable Disease Severe | Recurrent infection
Item
active, severe infection or history of recurrent clinically significant infection
boolean
C0009450 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0239998 (UMLS CUI [2])
C0205082 (UMLS CUI [1,2])
C0239998 (UMLS CUI [2])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Investigational New Drug
Item
treatment with an investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before baseline visit
boolean
C0013230 (UMLS CUI [1])
Intolerance to Methotrexate
Item
methotrexate intolerance
boolean
C1744706 (UMLS CUI [1,1])
C0025677 (UMLS CUI [1,2])
C0025677 (UMLS CUI [1,2])